Annual Report

With two blockbuster cancer drugs driving record revenue, all eyes are on Syndax's upcoming earnings call for its 2026 outlook and growth strategy.

Appian flips from a major loss to GAAP profitability in 2025, driven by strong cloud revenue, key AI contracts, and a positive outlook for 2026.

As Cherry Hill Mortgage preps its 2025 results, investors eye dividends and strategy amid high interest rates and a challenging housing market.

Riding a wave of innovation and strategic shifts, the cruise wellness leader posts record earnings and projects over $1B in 2026 revenue.

Hecla Mining posts a record $1.4B year, slashes debt, and sells a major gold mine to double down on its strategy to dominate the North American silver market.

As Jazz Pharmaceuticals preps for key investor talks, all eyes are on its blockbuster pipeline, revenue growth, and strategy to fend off competition.

Facing massive revenue declines and a shrinking coach network due to GLP-1 drugs, Medifast bets its future on a risky pivot from weight loss to metabolic health.

Essent Group boosts its dividend after a strong 2025, returning $700M to shareholders while making a strategic leap into the global P&C reinsurance market.

The retail REIT reports record-breaking leasing and strong profits for 2025, while executing a strategic portfolio overhaul and setting a confident tone for 2026.

Investors eye Globus Medical's upcoming report for a full-year look at its NuVasive integration, market trends, and a pivotal 2025 performance.

Skycorp Solar reported a 27% revenue surge driven by global expansion, but intense competition and rising costs led to a surprising net loss.

With major conferences ahead, clinical-stage MBX Biosciences aims to impress investors with its promising peptide therapies for endocrine and metabolic disorders.

TruGolf accelerates its stock repurchase program, signaling faith in its future as it unveils new AI-powered tech in a booming indoor golf market.

After a stellar 2025, Corpay is hitting the road for key investor conferences. Can it convince the market its impressive growth is just the beginning?

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.

The private jet operator posted record revenue with fewer planes, achieving its first-ever quarter of positive Adjusted EBITDA in a major turnaround.

The high-tech wheel maker's stock plummets 65% as it fails to meet listing rules, signaling deep financial and operational distress for the company.

The semiconductor giant posted a huge Non-GAAP profit but a stunning IFRS loss for 2025. What's behind the numbers and why are investors cheering?

Life sciences giant QIAGEN defies economic headwinds with strong 2025 results, signaling aggressive growth in single-cell analysis and bioinformatics.

With promising new pipeline data and a major earnings report looming, Aclaris Therapeutics heads to two investor summits, placing its strategy on display.